Erschienen in:
11.12.2018 | Colorectal Cancer
Biomarkers of Bad Biology: Curse or a Blessing?
verfasst von:
Sudeep Banerjee, MD, Jason K. Sicklick, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 2/2019
Einloggen, um Zugang zu erhalten
Excerpt
Epigenetic regulation of the cysteine dioxygenase type 1 (CDO1) gene is a frequent alteration across a wide variety of cancer types, including common (i.e., colorectal, prostate, breast cancers) and rare (i.e., gallbladder and esophagus) malignancies.
1–5 In these diseases, hypermethylation of the
CDO1 promoter results in decreased expression of CDO1 enzyme and reduced conversion of cysteine to cysteine sulfinic acid (CSA). Several studies have found that
CDO1 promoter hypermethylation, and resultant reduction of
CDO1 expression, directly correlates with disease progression, suggesting that CDO1 has a tumor suppressive effect. In turn,
CDO1 promoter hypermethylation is associated with poor prognosis.
1,6 Contrary to these reports, the current study, “Epigenetic status of
CDO1 gene may reflect chemosensitivity in colon cancer with postoperative adjuvant chemotherapy” by Yokoi et al., describe a paradoxical finding that high levels of
CDO1 promoter hypermethylation in patients with stage III colorectal cancer (CRC) have a better prognosis following resection.
7 This difference in outcome does not persist in subset analyses of patients who did not receive adjuvant chemotherapy. In fact, only patients with high
CDO1 promoter hypermethylation who received adjuvant oxaliplatin-based therapy had better overall survival. Through this careful, albeit retrospective analysis, the authors uncover a situation where the natural history of disease is reversed by systemic chemotherapy in patients with “bad” tumor biology. …
